D Yip
Overview
Explore the profile of D Yip including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
662
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jain A, Sjoquist K, Yip D
Ann Oncol
. 2020 Sep;
31(12):1778-1779.
PMID: 32976937
No abstract available.
2.
3.
Boulding T, McCuaig R, Tan A, Hardy K, Wu F, Dunn J, et al.
Sci Rep
. 2019 Dec;
9(1):18771.
PMID: 31801957
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
4.
Boulding T, McCuaig R, Tan A, Hardy K, Wu F, Dunn J, et al.
Sci Rep
. 2018 Jan;
8(1):73.
PMID: 29311580
Complex regulatory networks control epithelial-to-mesenchymal transition (EMT) but the underlying epigenetic control is poorly understood. Lysine-specific demethylase 1 (LSD1) is a key histone demethylase that alters the epigenetic landscape. Here...
5.
Mahmud A, Qu X, Yip D, Leveridge M, Mackillop W
Clin Oncol (R Coll Radiol)
. 2017 Jan;
29(4):239-247.
PMID: 28057403
Aims: Penile cancer is a rare malignancy in Western countries. The management guidelines are mainly derived from retrospective studies as there are no randomised trials. The primary objective of this...
6.
Day D, Kanjanapan Y, Kwan E, Yip D, Lawrentschuk N, Davis I, et al.
Intern Med J
. 2016 Aug;
46(11):1291-1297.
PMID: 27507629
Background: The role of cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) in the era of targeted therapies is currently undefined. In recent years, neutrophil-to-lymphocyte ratio (NLR) has emerged...
7.
Thewes B, Davis E, Girgis A, Valery P, Giam K, Hocking A, et al.
Int J Equity Health
. 2016 Jun;
15:90.
PMID: 27286811
Background: Indigenous Australians have poorer cancer outcomes in terms of incidence mortality and survival compared with non-Indigenous Australians. The factors contributing to this disparity are complex. Identifying and addressing the...
8.
Garvey G, Thewes B, He V, Davis E, Girgis A, Valery P, et al.
Support Care Cancer
. 2015 May;
24(1):215-223.
PMID: 26003424
Introduction: Indigenous Australians have a higher cancer incidence, worse mortality and are less likely to receive optimal cancer treatment compared with non-Indigenous Australians. Culturally appropriate supportive care helps ensure that...
9.
Brule S, Jonker D, Karapetis C, OCallaghan C, Moore M, Wong R, et al.
Eur J Cancer
. 2015 May;
51(11):1405-14.
PMID: 25979833
Background: Right- and left-sided colon cancers (RC, LC) differ with respect to biology, pathology and epidemiology. Previous data suggest a mortality difference between RC and LC. We examined if primary...
10.
Kuo J, Parakh S, Yip D
J Clin Pharm Ther
. 2014 Apr;
39(4):446-8.
PMID: 24707992
What Is Known And Objective: Regorafenib improves progression-free survival as a late-line treatment for patients with metastatic gastrointestinal stromal tumour (GIST). As a multitargeted tyrosine kinase inhibitor (TKI), the expected...